IHV Scientific Advisory Board
Mario Stevenson, Ph.D., Chair
University of Miami
Mario Stevenson, Ph.D., is Chief of the Division of Infectious Diseases within the Miller School of Medicine at the University of Miami. Dr. Stevenson comes to the Miller School of Medicine from the University of Massachusetts. He spent twelve years as their Director of their Center for AIDS Research and building that program to the international status it now enjoys. In addition to his academic responsibilities, Stevenson finds time to contribute to many scientific societies and research boards. Most notably, he has been Adjunct Trustee for the American Foundation for AIDS Research (amfAR) as well as Chair of their Scientific Advisory Board for over five years. In the year 2000, he was honored with the Merit Award from the National Institutes of Health for his significant research efforts.
Dean Goldschmidt recently said of Dr. Stevenson, that "[he] is an extraordinary individual whose scientific accomplishments rank him within the top 1 percent of his peers, and whose contribution to our academic reputation will be substantial. Furthermore, he will provide invaluable help in accessing an NIH award, center for AIDS research, CFAR-P30 grant, and establish UM as a top tier AIDS research center." Dr. Stevenson will manage the division in collaboration with Michele Morris, M.D., Associate Professor Clinical Medicine, and Director of the Immunocompromised Host Section, who was recently promoted to the position of Clinical Chief of the Division of Infectious Diseases.
Edward Berger, Ph.D.
Edward A. Berger, Ph.D., is the Chief of the Molecular Structure Section of Laboratory of Viral Diseases at the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Berger earned his B.S. in chemistry from City College of the City University of New York in 1968. He received his Ph.D. in biochemistry and molecular biology in 1973 from Cornell University. He went on to do a postdoctoral fellowship in the department of genetics, biochemistry, and neurobiology at Stanford University School of Medicine from 1973 to 1976 and another fellowship in the department of cellular and developmental immunology at Scripps Clinical and Research Foundation from 1976 to 1977. He was a staff scientist with the Cell Biology Group at the Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts, from 1977 to 1987.
Berger’s awards and honors include: American Academy of Microbiology Fellow; Bernard Fields Memorial Lectureship, CROI 2007;1st NIH World AIDS Day Award 2006; ISI Highly Cited Researcher, Breakthrough of the Year, Science 1996; AAAS-Newcomb Cleveland Prize 1997; Great Experiments; Kenneth Fong/Clontech Award; Novartis-Drew Award for Biomedical Science; Damon Runyon-Walter Winchell Foundation Most Prominent Alumni; AMA/NIAID Nathan Davis Award; NIH Outstanding Contributions to Education of Postbaccalaureate Trainees; Norman P Salzman Memorial Mentor Award in Virology, Honorable Mention He joined the NIAID Laboratory of Viral Diseases in 1987 and became chief of the Molecular Structure Section in 1995.
Lieping Chen, M.D., Ph.D.
Yale University School of Medicine
Lieping Chen, M.D., Ph.D. studies membrane proteins that control lymphocyte function and translates his laboratory findings to treat human disease. Dr. Chen performed the first proof-of-concept study in 1992 showing the B7-CD28 family molecules serve as targets for cancer immunotherapy by introducing B7-1 into tumor cells to enhance therapeutic immunity. This study inspired subsequent studies targeting the B7-CD28/CTLA-4 family molecules to treat cancer. Dr. Chen discovered B7-H1 (PD-L1) in 1999 and demonstrated PD-L1's role in immune evasion in the tumor microenvironment. He singularly established the PD-1/PD-L1 pathway as a target for cancer immunotherapy in 1999-2002. He also initiated and organized the first-in-man anti-PD-1 clinical trial to treat human cancer in 2006 and developed PD-L1 staining as a biomarker to predict treatment outcomes. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against a broad spectrum of human cancers (first approved 2014, with five anti-PD-1/PD-L1 antibodies being FDA-approved since). Dr. Chen’s discoveries have revolutionized current oncology practices, treatments, and outcomes.
Dr. Chen’s laboratory has discovered numerous molecular pathways with immune modulatory functions, including 4-1BB (CD137), ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), LIGHT/HVEM, TROY, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM. These discoveries have led to the development of therapeutic agents in various stages of clinical trials, treating various types of human cancer and autoimmune disease.
He has published over 350 research articles, reviews, and book chapters. His discovery work on the PD-1/PD-L1 pathway was cited as the #1 breakthrough of the year by Science magazine in 2013. He has received several professional recognitions, including the William B. Coley Award (2014), AAI-Steinman Award (2016), Shizhang Bei International Award (2017), Warren Alpert Foundation Prize (2017), Luminary Award (2018) and Giants of Cancer Care (2018).
Carlo M. Croce，M.D.
The Ohio State University
Carlo M. Croce, MD, is Distinguished University Professor and The John W. Wolfe Chair in Human Cancer Genetics of the Department of Cancer Biology and Genetics, Director of the Human Cancer Genetics Program, and Director of the Institute of Genetics at The Ohio State University Comprehensive Cancer Center. His research has revealed the variety of mutated genes involved in leukemias, lymphomas and other cancers. During the course of his career, he discovered the juxtaposition of the human immunoglobulin genes to the MYC oncogene, the deregulation of MYC in Burkitt lymphoma, the ALL1/MLL gene involved in acute leukemias, the TCL1 gene associated with T-cell leukemias, and cloned, named and characterized the BCL2 gene involved in follicular lymphoma. In 2002 he discovered the role of microRNA in the pathogenesis of human cancer and then demonstrated that microRNA dysregulation contributes to the pathogenesis of all tumors. His discoveries have led to revolutionary innovations in the development of novel and successful approaches to cancer prevention, diagnosis, monitoring and treatment, based on gene-target discovery, verification and rational drug development.
Dr. Croce is a member of the National Academy of Sciences, Institute of Medicine (National Academy of Medicine), American Academy of Arts and Sciences, an AAAS Fellow and Fellow of the AACR Academy. His awards and honors include: Outstanding Investigator Award, The National Institutes of Health; General Motors Cancer Research Foundation – Charles S. Mott Prize; Robert J. and Claire Pasarow Foundation Cancer Award; AACR-Pezkoller International Award for Cancer Research; G.H.A. Clowes Memorial Award; Albert Szent-Györgyi Prize for Progress in Cancer Research; Health Prize of the Fund InBev-Baillet Latour, Leuven, Belgium; Dan David Prize, Dan David Foundation at Tel Aviv University, shared with Prof. Mary-Claire King and Prof. Bert Vogelstein. He is principal investigator on several federal research grants, has more than 1100 peer-reviewed, published research papers and an H index of 214.
William DeGrado, Ph.D.
University of California, San Francisco
William F. DeGrado, Ph.D., is the Principal Investigator of the DeGrado Lab and Professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco’s School of Pharmacy. He is also an Investigator at UCSF’s Cardiovascular Research Institute. His research interests include de novo protein design; membrane proteins; small molecule drug discovery for antimicrobials, influenza A virus, antifibrotics, and neurodegeneration; chemical biology; and peptide design.
Before coming to UCSF, DeGrado served as a Professor in the Department of Biochemistry and Biophysics at the UPenn School of Medicine and as Senior Director of the Medicinal Chemistry Department at DuPont Merck Pharmaceutical Company. His awards and honors include the American Chemical Society’s Ralph F. Hirschmann Award in Peptide Chemistry; the Peptide Society’s Merrifield Award, the DuPont Merck Summit Award, and the Eli Lilly Award in Biological Chemistry. He is a Fellow at the American Association for the Advancement of Science and serves as President of the Protein Society. DeGrado serves on the Editorial Board of Current Opinion in Chemical Biology. He received his B.A. in Chemistry from Kalamazoo College in 1977 and his Ph.D. in Chemistry from the University of Chicago. He is author of 374 publications and has been issued 29 U.S. patents.
Max Essex, D.V.M., Ph.D.
Harvard AIDS Institute
Dr. Myron (Max) Essex is Chair of the Harvard AIDS Initiative (HAI), the Lasker Professor of Health Sciences at Harvard University, and Chair of the Botswana–Harvard AIDS Institute (BHP). He received his DVM degree at Michigan State University, his Ph.D. at the University of California Davis, and was a postdoctoral fellow in the Department of Tumor Biology at the Karolinska Institute School of Medicine in Stockholm. Essex has published over 580 research papers; more than 40 have been in the journals Science and Nature. He has edited 10 books, including AIDS in Africa and Emerging Infections in Asia. His most recent book is Saturday Is for Funerals, published in 2010 and coauthored with AIDS activist and former Botswana Supreme Court Justice, Unity Dow.
He has trained 27 doctoral research students and 60 postdoctoral fellows. Essex has received 9 honorary degrees. He is an elected member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Microbiology. In 2007, the Harvard School of Public Health established the Essex Fellowship for Students from Africa in his honor. In November 2011 Essex received the IHV Lifetime Achievement Award for Scientific Contributions.
Warner C. Greene, M.D., Ph.D.
Gladstone Institute of Virology and Immunology
Dr. Warner C. Greene is the Director and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is also a Professor of Medicine, Microbiology and Immunology at the University of California, San Francisco (UCSF). The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying the pathogenic effects of HIV infection, with special emphasis on the function of the HIV nef, vif, and vpr gene products.
He is the author of more than 330 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as GIVI’s Founding Director in 1991. Dr. Greene is a member of the Institute of Medicine of the National Academies, a Fellow of the American Academy for the Advancement of Science, and in 2012 was inducted as President of the American Association of Physicians.
He also serves as Co-Director of the UCSF-GIVI Center for AIDS Research. In 2007, Dr. Greene was appointed President of the Accordia Global Health Foundation, whose mission is to overcome the burden of infectious diseases by building healthcare capacity and strengthening academic medical institutions in Africa .Among his numerous honors, Dr. Greene won the 2012 Distinguished Research Career Award from the Ohio State University Center for Retrovirus Research and the 2012 Alumni Achievement Award from The Washington University School of Medicine in St. Louis.
In 2012, Dr. Greene joined with other global AIDS experts to release a locally affordable version of the world’s leading AIDS medical textbook, Sande’s HIV/AIDS Medicine: Global Care. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard.
Diane E. Griffin M.D., Ph.D.
Johns Hopkins Bloomberg School of Public Health
Diane E. Griffin M.D., Ph.D. is University Distinguished Service Professor and former chair of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health and Vice President of the US National Academy of Sciences. She earned her MD and PhD from Stanford University School of Medicine. Her research interests are in the area of pathogenesis of viral diseases with a focus on measles and alphavirus encephalitis. These studies address issues related to virulence and the role of immune responses in protection from infection and in clearance of infection and has included evaluation of licensed and experimental vaccines for measles. She is past president of the American Society for Virology and the American Society for Microbiology. Currently, she is US Chair of the US-Japan Cooperative Medical Sciences Program and Director of the Johns Hopkins Global Virus Network Center of Excellence.
Mark H. Kaplan, M.D.
University of Michigan Health System
Mark H. Kaplan, formerly the Jane and Dayton T. Brown Professor at New York University School of Medicine, was at North Shore University Hospital for 25 years as Chief of Infectious Diseases, founding and serving as director of the Center for AIDS Research and Treatment. Currently, he is Professor of Clinical Medicine at the University Of Michigan Health System Department Of Medicine, Infectious Diseases Division, where he conducts research on AIDS lymphoma, Human Endogenous Retrovirus activation in HIV and ELF-3 in breast cancer. He has published 144 peer-reviewed papers in infectious diseases, along with several books and book chapters on pathogenesis, diagnosis, and treatment of infectious diseases. For years he has been named one of the "Best Doctors" in New York, in the Northeast and in America.
Michel Klein, M.D.
Dr. Klein is Chairman of VaxiBio Inc., a new vaccine biotechnology company registered in Canada with a subsidiary in Taiwan. His experience includes Vice President Biotechnology Research – Pasteur Mérieux Connaught Canada; Professor of Immunology – University of Toronto; Corporate Vice President, Science and Technology – Aventis Pasteur Group and Chief Executive Officer, CANVAC (Canadian Network for Vaccines and Immunotherapeutic).
John W. Mellors, M.D.
University of Pittsburgh
John W. Mellors, M.D., is a tenured Professor of Medicine, Chief of Infectious Diseases and the Endowed Chair for Global Elimination of HIV and AIDS at the University of Pittsburgh School of Medicine. He is also the Executive Director of the HIV Program at the University of Pittsburgh Medical Center (UPMC), which provides comprehensive primary care and access to clinical trials for HIVinfected individuals. Dr. Mellors' research focuses on the mechanisms of HIV drug resistance, on the use of antiretrovirals to prevent HIV-1 infection, and on persistent reservoirs of HIV-1 resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, the role of low frequency drug-resistant HIV-1 variants in failure of antiretroviral therapy, and the source of persistent viremia in patients on "successful" antiretroviral therapy. His clinical research efforts helped establish the relationship between viremia and clinical outcome in HIV-1 infection and between drug resistance and treatment response in antiretroviral-experienced patients. Dr. Mellors directs the virology cores for the AIDS Clinical Trials Group and the Microbiocide Trials Network. He is an elected member of the Association of American Professors.
Douglas Nixon, M.D., Ph.D.
The George Washington University
Douglas Nixon, M.D., Ph.D., is the Ross Professor of Basic Science Research and chair of the Department of Microbiology, Immunology, and Tropical Medicine (MITM) at the GW School of Medicine and Health Sciences (SMHS). Nixon has actively pursued immunovirology research for more than 25 years, with his studies spanning from clinical research and human immunology, to basic virology and molecular biology.
Over the past two decades, he has focused on the cellular immune response to retrovirus infections and has published extensively on these topics. Most recently, Nixon was a professor of medicine at the University of California, San Francisco, and associate chief of the division of experimental medicine, where he served as the primary mentor for numerous postdoctoral fellows, students, and several National Institutes of Health (NIH) Individual Career Development (K) awardees. He has also held positions at the Gladstone Institute of Virology and Immunology, The Rockefeller University, the Aaron Diamond AIDS Research Center, and the University of Oxford. Among his many accomplishments, Nixon gained recognition for publishing the first identification of an HIV specific cytotoxic T cell CTL epitope in the journal Nature.
In addition, he has published more than 190 articles in peer-reviewed journals, including first- or senior-author publications in Nature, PNAS, Journal of Clinical Investigation, PLoS Pathogens, and he holds several patents. Nixon’s research is funded through grants from the NIH, including an NIH Merit Award, AmfAR, and the Gates Foundation. He is the chair of the NIH AIDS Vaccine Subcommittee, was elected as a scientist of the Elizabeth Glaser Pediatric AIDS Foundation, is a member of the American Society for Clinical Investigation and the Henry Kunkel Society, and delivered the Distinguished Science Lecture in 2009 at the NIH Rocky Mountain Laboratories.
Nixon also reviews for many publications, including Nature, Science, and Cell. Recently, Nixon was named as one of the 2012 POZ 100, which is an elite group of scientists, researchers, advocates, politicians, and celebrities who are recognized by POZ Magazine for their significant contributions to speeding up the end of AIDS.
Erling C. J. Norrby, M.D., Ph.D.
Secretary General, The Royal Swedish Academy of Sciences
Erling Norrby, M.D., Ph.D. is from the Karolinska Institute, the School of Medicine, Stockholm. He is a world authority on viruses and was professor and chairman at the Institute for 25 years. During this time he was President of the Division of Virology representing all the virologists of the world for three years. He has also served as the Dean of the Medical Faculty for six years and has been heavily involved in various ways for more than 20 years in the selection of the recipients of Nobel Prizes in Physiology or Medicine. He then left to become the Permanent Secretary of the Royal Swedish Academy of Sciences for six years.
During this time he had overriding responsibility for the Nobel Prizes in Physics and in Chemistry and was a member of the Board of the Nobel Foundation. He has lectured around the world on many topics related to the Nobel Prizes. Currently, he is the Vice-Chairman of the Board of the J. Craig Venter Institute. He also has one of the leading functions at the Royal Swedish court as Lord Chamberlain in Waiting.
Joseph Pagano, M.D.
University of North Carolina
Joseph S. Pagano, M.D., is Lineberger Professor of Cancer Research and Professor of Medicine and Microbiology and Immunology, The University of North Carolina at Chapel Hill. He is Founder and Director Emeritus of The Lineberger Comprehensive Cancer Center and Director of the UNC-LCCC Postdoctoral Training Program.
He is Member of the Science Advisory Board of the US Food and Drug Administration, the Institute of Medicine of the National Academy of Science, the College of Reviewers of the National Institutes of Health, and Fellow of the American Association for Advancement of Science. Dr. Pagano is past member of the Board of Directors of the Burroughs Welcome Fund and the Awards Assembly of the General Motors Cancer Research Foundation and past president of the Association of American Cancer Institutes and the International Association for Research on Epstein - Barr virus and Associated Diseases.
Dr. Pagano is the recipient of The North Carolina Award in Science. He is Chairman of the Board of Global Vaccines, Inc., a not-for-profit company, and external advisor to cancer centers at Wake Forest, Miami, Georgetown, Pittsburgh and Pennsylvania Universities, as well as the Wistar Institute, and chairs the Science Advisory Board of the Institute of Human Virology. He is member of the Board of Directors of the Hamner Institutes.
His research interests are molecular virology and pathogenesis of diseases caused by viruses associated with human malignancies and mechanisms of antiviral drugs. He is discoverer of the EBV episome and Interferon Regulatory Factor-7 and is currently working on the ubiquitin-editing enzyme, UCH LI, and the EBV protein kinase and deubiquitinating enzymes. His research is funded by the National Institutes of Health and the National Cancer Institute. He is author of 356 publications.
Peter Palese, Ph.D.
Mount Sinai School of Medicine
Dr. Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. His research includes work on the replication of RNA-containing viruses with a special emphasis on influenza viruses, which are negative-strand RNA viruses. Specifically, he established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals).
Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/ function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. In addition, an improvement of the technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent but extinct 1918 pandemic influenza virus. His recent work in collaboration with Garcia-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host.
Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses. At present he serves on the editorial board for the Proceedings of the National Academy of Sciences. He has been a Corresponding Member of the Austrian Academy of Sciences since 2002 and a Member of the German Academy of Sciences Leopoldina since 2006. Dr. Palese was president of the Harvey Society in 2004/2005 and president of the American Society for Virology in 2005/2006. He was the recipient of the Robert Koch Prize in 2006, of the Charles C. Shepard Science Award in 2008 and of the European Virology Award (EVA) in 2010.
Jeffrey V. Ravetch, M.D., Ph.D.
Jeffrey V. Ravetch, M.D., Ph.D. is currently the Theresa and Eugene Lang Professor at the Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology. Dr. Ravetch, a native of New York City, earned degrees from Yale University, Cornell Medical College and The Rockefeller University and pursued postdoctoral studies at the NIH. From 1982 to 1996 Dr. Ravetch was a member of the faculty of Memorial Sloan-Kettering Cancer Center and Cornell Medical College.
His laboratory has focused on the Fc domain of antibodies and their receptors, establishing their structural and functional diversity and the pre-eminence of FcR pathways in host defense, inflammation and tolerance. His work has been widely extended into clinical applications for the treatment of neoplastic, inflammatory and infectious diseases. Dr. Ravetch has received numerous awards including the William B. Coley Award (2007), Sanofi-Pasteur Award (2012), Gairdner International Prize (2012), Wolf Prize in Medicine (2015), Ross Prize in Molecular Medicine (2017) and the Robert Koch award (2018). He is a member of National Academy of Sciences (2006), the National Academy of Medicine (2007), a Fellow of the American Academy of Arts and Sciences (2008) and a Fellow of the American Association for the Advancement of Science (2009).
Ravetch has contributed extensively to the scientific community by serving as a member of the Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Medical Research, the Damon Runyon Foundation, the medical advisory board of Gairdner Foundation, the Sanofi-Pasteur Award Jury and the L’Oreal Women in Science Jury. He has been active in biotechnology for the last two decades, and currently serves as a consultant or member of the Scientific Advisory Boards of Harpoon, Janssen, Kleo, Momenta, Palleon, Portola and Xencor.
Michael S. Saag, M.D.
University of Alabama at Birmingham Center for AIDS Research
Dr. Saag is Professor of Medicine and Director of the UAB Center for AIDS Research. During his fellowship in Infectious Diseases, Dr. Saag conceived the concept of a comprehensive HIV outpatient (1917) clinic dedicated to the provision of comprehensive patient care in conjunction with the conduct of high quality clinic trials, basic science, and clinical outcomes research. Over the last 25 years, the clinic has treated more than 9000 patients and has become recognized as one of the best sites for clinical research and care in the United States. Dr. Saag has published over 300 articles in peer reviewed journals, including the first description of the use of viral load in clinical practice (Science, 1993), the first description of the rapid dynamics of viral replication (Nature, 1995), the first guidelines for use of viral load in practice (Nature Medicine, 1996), the first proof of concept of fusion inhibition as a therapeutic option (Nature Medicine, 1998), and directed the ‘first-in- patient’ studies of 7 of the 25 antiretroviral drugs currently on the market (including indinavir, efavirenz, abacavir, and enfuvirtide).
Dr. Saag has received the Myrtle Wreath Award from Hadassah, was listed as one of the top ten cited HIV researchers by Science (1996), and received two Argus Awards in 2009 for Best Lectures to the 1st year medical students at UAB and another Argus Award in 2010 and 2011. In December 2010, he was awarded the President’s Medal of UAB, the highest honor given at this institution. In 2014, Dr. Saag was named the Castle-Connolly National Physician of the Year Award for Clinical Excellence. Dr. Saag just finished a memoir entitled, “Positive: One doctor’s encounters with death, life, and the US Healthcare System,” which was released in the April 2014.
Erica Ollmann Saphire, Ph.D.
The Scripps Research Institute
Dr. Ollmann Saphire's laboratory explores, at the molecular level, how pathogens evade and usurp innate and adaptive immune responses and how we can design vaccines and antivirals to defend against them. She incorporates x-ray crystallography, virology, and immunology in her analysis of the key proteins responsible for the pathogenesis of and immune suppression in Lassa, LCMV, Marburg, and Ebola Hemorrhagic Fevers. Dr. Ollmann Saphire's awards include a Presidential Early Career Award in Science and Engineering (PECASE) presented by The White House Office of Science and Technology Policy and NIH/NIAID in 2009, the Burroughs Wellcome Career Award in Biomedical Sciences, the American Society of Microbiology’s ICAAC Young Investigator Award, the Ellison Medical Foundation’s New Initiatives Award in Global Infectious Disease, and the Pittsburg Diffraction Society’s Surhain Sidhu Award.
Jeffrey Schlom, Ph.D.
National Cancer Institute, NIH
Dr. Schlom is Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research at the National Cancer Institute, National Institutes of Health. He directs a translational research program focusing on the design and development of new cancer immunotherapies and immunotherapeutic strategies. The program takes advantage of the latest advances in genomics and immunology through hypothesis-generating preclinical research and translates these findings into paradigm-shifting science-based clinical trials.
Novel immunotherapies designed or developed in this program include therapeutic cancer vaccines, checkpoint inhibitors, immune modulators, and agents to inhibit immunosuppressive entities. Emphasis is placed on the development of "off the shelf" therapeutics that can be widely distributed and evaluated at multiple cancer research centers.
Dr. Schlom’s program has also developed a spectrum of immune assays that interrogates numerous components of the immune system, to help identify which patients will most likely benefit from immunotherapy either before treatment is initiated or early in the therapeutic regimen. Dr. Schlom serves on the editorial boards of numerous scientific journals, and has received numerous awards. He holds a wide range of patents in the area of immunotherapy and has authored more than 700 scientific publications.
Anna Marie (Ann) Skalka, Ph.D.
Fox Chase Cancer Center
Dr. Ann Skalka is Professor Emerita and former W.W. Smith Chair in Cancer Research at the Institute for Cancer Research at the Fox Chase Cancer Center in Philadelphia, where she served as Sr. Vice President for Basic Science from 1987 until 2008. She received a Ph.D. degree in Microbiology from New York University Medical School. Dr. Skalka is internationally recognized for her contributions to our understanding of viral oncogenesis and for the biochemical mechanisms by which retroviruses (including the AIDS virus) replicate and insert their genetic material into the host genome. Work from her laboratory provided fundamental groundwork for development of antiviral drugs to treat AIDS.
Dr. Skalka has published more than 240 scientific papers and scholarly reviews, has edited several scientific books, and organized and spoken at numerous national and international meetings and conferences. She is also author of Discovering Retroviruses: Beacons in the Biosphere, a history-focused book for the science-interested public published in 2018 by Harvard University Press, and is coauthor of the widely acclaimed, two-volume textbook, Principles of Virology. In addition to service on numerous scientific advisory boards,
Dr. Skalka has been deeply involved in state, national, and international advisory groups concerned with the broader, societal implications of scientific research, including the NJ Commission on Cancer Research, which she chaired from 2008-2013. In recognition of her outstanding accomplishments, she has been honored by election to the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the New York Academy of Science, and the American Academy of Microbiology, and by several prestigious awards including the 2018 Sigma Xi William Procter Prize for Scientific Achievement and Communication.
David Thomas, M.D., M.P.H.
Johns Hopkins Medicine
David Thomas, M.D., M.P.H. is Chief of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. His research is focused on hepatitis C virus (HCV). Dr. Thomas is a member of ASCI (2001), AAP (2011), and the Infectious Diseases Association of America from whom he was given the Society Citation Award in 2014.
Sten H. Vermund, M.D., Ph.D.
Yale School of Public Health
Sten H. Vermund, M.D., Ph.D., serves as Dean of the Yale School of Public Health, Anna M.R. Lauder Professor of Public Health (Epidemiology of Microbial Diseases) and Professor of Pediatrics, Yale School of Medicine. His work on HIV-HPV interactions among women in a methadone program in the Bronx stimulated a change in the 1993 CDC AIDS case surveillance definition to include cervical cancer and helped motivate the launch of cervical cancer screening programs within HIV/AIDS programs around the world. His research has focused on health care access in low income nations, adolescent sexual and reproductive health, and prevention of mother-to-child HIV transmission. He is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.